Martin Shkreli’s net worth today is uncertain and probably small, and it may even be negative once his court-ordered obligations are counted. At his 2015 peak, when he ran Turing Pharmaceuticals and still held Retrophin shares, his paper wealth was estimated in the tens of millions of dollars, with some reports citing figures around $70 million.
Since then he has been convicted of securities fraud, forfeited about $7.4 million in assets and been ordered to repay $64.6 million tied to the Daraprim strategy. No reliable, current public figure exists, so anyone quoting a precise number is guessing. What follows is a documented account of how the money was made, how most of it was lost, and how to read the estimates you will see online.
Martin Shkreli: Quick Facts
| Detail | Information |
|---|---|
| Full name | Martin Shkreli |
| Born | March 17, 1983, Brooklyn, New York |
| Education | Bachelor’s degree in business administration, Baruch College (2004) |
| Known for | Hedge funds including MSMB Capital, founder of Retrophin and Turing Pharmaceuticals, the Daraprim price increase |
| Criminal conviction | Securities fraud and conspiracy, August 2017 |
| Sentence | Seven years in federal prison (March 2018); released in 2022 |
| Forfeiture | About $7.36 million, including the Wu-Tang Clan album |
| Civil judgment | $64.6 million disgorgement and a lifetime pharmaceutical industry ban (January 2022) |
| Estimated net worth | Not reliably known; likely a small fraction of his peak |
Why Estimates of His Net Worth Vary So Much
Websites have published figures for Shkreli ranging from under $1 million to $70 million or more. That spread is not because anyone has new information; it comes from three recurring problems in how celebrity net worth is calculated.
- Stale peak figures. The higher numbers mostly date from 2015, when his wealth sat largely in shares of companies he founded. The value of those stakes, and his control over them, changed after he was pushed out of Retrophin and later prosecuted.
- Liabilities are ignored. A federal court ordered him to disgorge $64.6 million. Many estimates list assets but never subtract that obligation, which is the single largest number in his financial picture.
- Private holdings. His later ventures are private companies, so their value, if any, is not disclosed.
Put simply, the useful question is not how much he once controlled but how much would remain after judgments, forfeiture and legal costs. On the public record, that number is unclear and unlikely to be large.
How Net Worth Is Actually Calculated
Net worth is total assets minus total liabilities. For a public figure, assets might include cash, property, company shares and collectibles, while liabilities include loans, tax bills and court judgments. With Shkreli, the asset side is mostly unknown after 2017, but the liability side contains a very large, well-documented figure. That imbalance is why most careful observers describe his current position as modest at best.
Early Life and First Jobs in Finance
Shkreli grew up in Brooklyn, the son of immigrants from Albania and Croatia who worked as janitors. As a teenager he took a job as a clerk at Cramer Berkowitz, the hedge fund co-founded by Jim Cramer, where he developed an interest in biotech stocks. He earned a business degree from Baruch College in 2004 while already working in the industry.
He went on to start his own funds, Elea Capital and then MSMB Capital Management, which traded heavily in small biotech companies and often took short positions, betting that share prices would fall. Those funds were later at the center of his criminal case, because prosecutors said he misled investors about how they were performing.
How He Built His Wealth
Retrophin
In 2011 Shkreli founded Retrophin, a biotech company focused on rare diseases, and took it public through a reverse merger. His stake in the listed company was the main source of his paper wealth during this period.
The board removed him as chief executive in 2014, and Retrophin later sued him, alleging he had used company money and shares to settle debts owed to investors in his failed hedge funds. That dispute fed directly into the federal case brought against him.
Turing Pharmaceuticals and Daraprim
In 2015 he founded Turing Pharmaceuticals, later renamed Vyera. Turing bought the US rights to Daraprim, a decades-old drug used to treat toxoplasmosis, a parasitic infection that can be life-threatening for people with weakened immune systems, including some people living with HIV. It then raised the price from $13.50 to $750 per tablet, an increase of more than 5,000%.
The move made Shkreli a national symbol of drug price gouging and triggered investigations by Congress and regulators. Turing’s profits from the drug were substantial, but they belonged to the company rather than directly to Shkreli. Regulators later pursued those profits through a separate civil case.
Purchases That Became Famous
In 2015 Shkreli paid a reported $2 million for “Once Upon a Time in Shaolin”, a one-copy Wu-Tang Clan album. The purchase added to his notoriety, and the album was forfeited to the government as part of his sentence. It was sold in 2021 to the collective PleasrDAO, reportedly for around $4 million. In 2024 a court ordered him to hand over any copies of the music he had kept.
Where the Money Went: The Legal Timeline
| Date | Event | Financial effect |
|---|---|---|
| September 2014 | Removed as Retrophin CEO | Loses control of main company; later sued by it |
| December 2015 | Arrested on securities fraud charges | Resigns from Turing and from KaloBios, which he had briefly led |
| August 2017 | Jury convicts him on three of eight counts | Two counts of securities fraud and one of conspiracy |
| March 2018 | Sentenced to seven years | Ordered to forfeit about $7.36 million |
| January 2022 | FTC and New York-led antitrust case decided | Ordered to repay $64.6 million and banned from the pharmaceutical industry for life |
| 2022 | Released from federal custody | Starts new ventures under legal restrictions |
The Criminal Case
The criminal case concerned his hedge funds and Retrophin, not Daraprim. Prosecutors argued that he lied to hedge fund investors about performance and then used Retrophin assets to repay them. Jurors acquitted him on several counts, and investors ultimately got their money back, but that did not change the verdict on the counts where he was convicted. The forfeiture order that followed is what cost him the Wu-Tang album and other assets.
The Civil Antitrust Case
The later civil case targeted the Daraprim strategy itself. The Federal Trade Commission, joined by several states led by New York, argued that Turing and Shkreli had illegally blocked cheaper generic competitors, partly by restricting how the drug was distributed so generic makers could not easily obtain samples for testing. The judge agreed, ordering him to return $64.6 million and barring him from the pharmaceutical industry for life. Vyera and its parent company settled separately.
Public Conduct That Raised the Stakes
Shkreli’s behavior in public repeatedly made his legal and financial position worse. In February 2016 he appeared before a House committee investigating drug prices, invoked his Fifth Amendment right not to answer questions, and shortly afterwards called lawmakers “imbeciles” on social media. The episode added to the political pressure around Turing.
After his conviction, a judge revoked his bail in September 2017 over a social media post offering money for a strand of Hillary Clinton’s hair, which the court treated as a potential threat. As a result he spent the period before sentencing in jail. His constant streaming and posting also gave prosecutors and regulators a large public record to draw on.
The costs of that conduct can be grouped into three areas:
- Reputational cost: partners, lenders and investors became reluctant to work with him, which limits access to capital for any new venture.
- Legal cost: bail revocation and the lifetime industry ban reduced his options for earning money in the field he knew best.
- Financial cost: legal fees across the criminal and civil cases, which are not public but were likely significant.
Life and Business After Prison
Since his release, Shkreli has been active online and has launched new ventures, including a software project aimed at drug discovery that he described as compatible with the industry ban because it does not involve making or selling drugs. He has also been involved in crypto and online streaming projects.
None of these has a publicly reported valuation. Until one of them produces disclosed revenue, a funding round or a sale, the $64.6 million judgment remains the dominant fact in any assessment of his personal finances.
Peak Versus Present: A Summary
| Factor | Around 2015 | Today |
|---|---|---|
| Main assets | Shares in Retrophin and Turing, fund interests | Private stakes in newer ventures, value unknown |
| Notable collectibles | Wu-Tang Clan album | Forfeited and sold by the government |
| Liabilities | Investor disputes, pending lawsuits | $64.6 million disgorgement order |
| Earning restrictions | None | Lifetime pharmaceutical ban |
| Reported estimates | Tens of millions, some around $70 million | No reliable figure; widely thought to be small |
How to Judge Any Net Worth Figure You See
If you come across a confident number for Shkreli or any other public figure with legal troubles, run it through a quick checklist:
- Does the source say when the figure was calculated? A 2015 number is not a current number.
- Does it subtract court judgments, forfeiture and known debts, or does it only add up assets?
- Does it cite court records, filings or reputable reporting, or does it simply repeat another site?
- Does it value private companies without any disclosed funding or revenue? If so, treat it as speculation.
For Shkreli, a figure that fails these checks is not worth much, which is why this article gives a range of possibilities rather than one precise number.
What the Shkreli Story Shows About Drug Pricing
The Daraprim case highlighted a weakness in the US drug market. Old, off-patent drugs with only one supplier can see enormous price increases if potential competitors face barriers to entry, such as restricted distribution that prevents generic makers from obtaining samples. The FTC case against Shkreli is often cited as an example of regulators using antitrust law to challenge that tactic, and a generic version of Daraprim reached the market in 2020.
Bottom Line on Martin Shkreli’s Net Worth
Martin Shkreli was once worth tens of millions on paper, almost entirely through shares in companies he founded. Removal from Retrophin, a fraud conviction, a $7.36 million forfeiture and a $64.6 million disgorgement order have since wiped out most of that, and his newer ventures have no public valuation. Treat any precise figure with caution: the most defensible answer is that his net worth is unknown, far below its peak and possibly below zero.
Frequently Asked Questions
What is Martin Shkreli’s net worth now?
There is no reliable current figure. After forfeiting about $7.36 million and being ordered to repay $64.6 million, his net worth is widely thought to be far below his 2015 peak and could be negative.
How did Martin Shkreli make his money?
Mainly through his hedge funds and his stakes in the biotech companies he founded, Retrophin and Turing Pharmaceuticals. His peak wealth was largely on paper, tied to the value of those shares.
Why did Martin Shkreli go to prison?
He was convicted in 2017 of two counts of securities fraud and one count of conspiracy related to his hedge funds and Retrophin, and sentenced to seven years in 2018. The criminal case was not about the Daraprim price increase.
How much did Turing raise the price of Daraprim?
In 2015 Turing raised the price from $13.50 to $750 per tablet, an increase of more than 5,000%. A generic version of the drug reached the market in 2020.
What happened to the Wu-Tang Clan album?
It was forfeited to the US government as part of his sentence and sold in 2021 to the collective PleasrDAO. In 2024 a court also ordered him to hand over any copies of the music he had kept.
Can Martin Shkreli work in the pharmaceutical industry again?
No. The January 2022 ruling in the FTC and state antitrust case banned him from the pharmaceutical industry for life, alongside the $64.6 million repayment order.
